Aromatase inhibitors are an effective treatment for ER+ breast cancer, but response is variable. Here, the authors undertake molecular analyse of response from the POETIC trial and identify several factors associated with response.
- Eugene F. Schuster
- Elena Lopez-Knowles
- Mitch Dowsett
